BRIEF published on 12/11/2024 at 12:13, 1 year 1 month ago Threshold crossing by Bpifrance in ABIONYX PHARMA Voting Rights Actions Threshold Crossing Bpifrance ABIONYX
BRIEF published on 12/10/2024 at 10:51, 1 year 1 month ago Threshold crossing by Cyrille Tupin at ABIONYX PHARMA Voting Rights Actions Threshold Crossing ABIONYX Pharma Cyrille Tupin
BRIEF published on 11/14/2024 at 19:05, 1 year 2 months ago ABIONYX Pharma: Third quarter 2024 financial report Biotechnology Treasury Turnover Q3 2024 ABIONYX Pharma
PRESS RELEASE published on 11/14/2024 at 19:00, 1 year 2 months ago Quarterly financial reporting / Third quarter financial report ABIONYX Pharma reports Q3 2024 revenue of €3.4m and cash position of €4.1m before IRIS Pharma's CIR receipt. General Meeting on November 28, 2024, at 2.00 pm CET Cash Position General Meeting Biotech Company ABIONYX Pharma Revenue Update
BRIEF published on 10/24/2024 at 19:35, 1 year 3 months ago ABIONYX Pharma presents the results of the RACERS study ABIONYX Pharma CER-001 Brain Fog Kidney Week Neuroinflammation
PRESS RELEASE published on 10/24/2024 at 19:30, 1 year 3 months ago Inside Information / Other news releases ABIONYX Pharma's RACERS study on CER-001 shows positive impact on cognitive impairment in brain-fog patients, presenting new clinical results at ASN 2024 Annual Meeting. Potential treatment for neuroinflammation ABIONYX Pharma CER-001 Brain-fog Neuroinflammation RACERS Study
BRIEF published on 10/21/2024 at 20:05, 1 year 3 months ago ABIONYX Pharma receives positive EMA opinion for CER-001 ABIONYX Pharma CER-001 EMA AMM LCAT Deficiency
PRESS RELEASE published on 10/21/2024 at 20:00, 1 year 3 months ago Inside Information / Other news releases ABIONYX Pharma receives positive feedback from EMA for CER-001 in LCAT Deficiency, allowing submission of data from 2 prospective process validation batches for MAA manufacturing ABIONYX Pharma CER-001 EMA LCAT Deficiency Process Validation Batches
BRIEF published on 08/22/2024 at 18:05, 1 year 5 months ago ABIONYX Pharma: Review of the first half of 2024 Biotechnology Fundraising Treasury Turnover ABIONYX Pharma
PRESS RELEASE published on 08/22/2024 at 18:00, 1 year 5 months ago Inside Information / Other news releases ABIONYX Pharma reports €2.4m sales and €5.3m cash position for H1 2024, focused on innovative therapies. Raised €3.4m for sepsis program in the US Sales Cash Position Innovative Therapies ABIONYX Pharma Sepsis
Published on 01/30/2026 at 02:15, 2 hours 56 minutes ago Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 5 hours 11 minutes ago LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
Published on 01/29/2026 at 23:00, 6 hours 11 minutes ago PPX Mining Announces Filing of 2025 Audited Financial Statements and MD&A
Published on 01/29/2026 at 18:45, 10 hours 26 minutes ago Silver Spruce Appoints Vice-President of Exploration
Published on 01/29/2026 at 18:00, 11 hours 11 minutes ago PPX Mining Announces Grant of Restricted Share Units and Deferred Share Units
Published on 01/30/2026 at 04:30, 41 minutes ago A First Look at AI in the Real World: AWE 2026 Opens This March in Shanghai
Published on 01/30/2026 at 03:35, 1 hour 36 minutes ago Bybit Unveils 2026 Vision as "The New Financial Platform," Expanding Beyond Exchange Into Global Financial Infrastructure
Published on 01/30/2026 at 00:07, 5 hours 4 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Appointment of independent non-executive director
Published on 01/29/2026 at 21:02, 8 hours 9 minutes ago Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
Published on 01/29/2026 at 21:01, 8 hours 10 minutes ago Form 8.3 - The Vanguard Group, Inc.: JTC plc
Published on 01/29/2026 at 18:00, 11 hours 11 minutes ago GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 11 hours 26 minutes ago LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 11 hours 26 minutes ago Cegedim generated LFL revenue growth of 1.1% in 2025
Published on 01/29/2026 at 10:07, 19 hours 4 minutes ago Deezer confirms demonetization of up to 85% of AI-music streams due to fraud and moves to sell AI-detection tech
